Mangalam Drugs & Organics Limited (NSE:MANGALAM)
India · Delayed Price · Currency is INR 29.36
+0.14 (0.48%)
Nov 11, 2026, 2:34 PM IST
Mangalam Drugs & Organics Revenue
Mangalam Drugs & Organics had revenue of 795.61M INR in the quarter ending September 30, 2026, with 61.51% growth. This brings the company's total for the last twelve months to 2.62B, down -2.16% year-over-year. In the fiscal year ending March 31, 2026, Mangalam Drugs & Organics had annual revenue of 2.32B, down -26.90%.
Revenue (ttm)
2.62B
Revenue Growth
-2.16%
P/S Ratio
0.18
Revenue / Employee
8.21M
Employees
319
Market Cap
465.99M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 2.32B | -854.43M | -26.90% |
| Mar 31, 2025 | 3.18B | -497.78M | -13.55% |
| Mar 31, 2024 | 3.67B | -28.42M | -0.77% |
| Mar 31, 2023 | 3.70B | -806.66M | -17.89% |
| Mar 31, 2022 | 4.51B | 708.84M | 18.65% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Sigachi Industries | 4.91B |
| Valiant Laboratories | 3.76B |
| Amanta Healthcare | 3.04B |
| Balaxi Pharmaceuticals | 2.80B |
| Alpa Laboratories | 1.11B |
| Vaishali Pharma | 1.08B |
| Par Drugs and Chemicals | 1.08B |
| Brooks Laboratories | 795.39M |